| Related Articles |
Acute Management of Hereditary Angioedema Attacks.
Immunol Allergy Clin North Am. 2017 Aug;37(3):541-556
Authors: Katelaris CH
Abstract
Several treatment modalities have become available for management of acute hereditary angioedema (HAE) attacks in the last 15 years. Most are now available to patients in North America, Europe, United Kingdom, and Australia, but few options exist in developing countries. Preferred contemporary use of the treatments to be discussed is "on demand," because control remains with the patient and delays in treatment access avoided. Four treatments-plasma-derived C1 inhibitor concentrate, recombinant C1 inhibitor concentrate, ecallantide, and icatibant-are reviewed in this article. All have been shown to be superior to placebo and effective in the management of all HAE attacks.
PMID: 28687108 [PubMed - in process]
from #ENT-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2uZPnRF
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.